Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this randomized trial, oral supplementation with Serenoa repens, pumpkin seed extracts, and cysteine significantly improved the clinical effectiveness of topical 5% minoxidil lotion for treating androgenic alopecia in men and women compared to minoxidil alone, with both treatments being well tolerated.

This study found that topical application of Serenoa repens extract increased hair count in men with androgenetic alopecia, suggesting it could be an alternative for those unable to use standard medications.

This article discusses the role of transplantation in hair restoration but reports no new clinical findings.

Researchers reviewed 13 clinical trials on non-prescription monotherapies like procyanidin and cetirizine for androgenetic alopecia, finding potential improvements in hair density and diameter, but emphasized the need for more robust trials to confirm efficacy and safety.

This review found inconsistent evidence on the effectiveness of oral finasteride for hair loss reversal in men with androgenetic alopecia, with one study showing significant results and others not.

This study suggests that a topical hydroalcoholic extract of liquorice root significantly reduced sebaceous gland size in Syrian hamsters, indicating potential for use in anti-acne therapy.

This article describes a clinical case of a 67-year-old patient with telogen effluvium treated with a supplement containing amino acids, vitamin E, iron, and Serenoa repens, but reports no new clinical findings.

This review discusses natural and botanical products examined for treating alopecia and reports no clinical results; the authors note growing research interest in these treatments.

This study found that platelet-rich plasma therapy significantly improved wound area and depth reduction in chronic wounds compared to pre-treatment, suggesting registry data can effectively complement traditional clinical trials.

This systematic review assessed the off-label use of topical Ruxolitinib cream for various skin conditions and found it effective for lichenoid and granulomatous dermatoses, though results for alopecia areata were inconsistent. The authors indicate that further research is warranted to confirm these findings.

This study found that topical minoxidil significantly enhanced facial hair growth in transgender individuals assigned female at birth undergoing gender affirming hormone therapy, with improvements most notable after six months of use.

This case report suggests that exosome therapy may offer a promising alternative treatment for lichen planopilaris, showing potential benefits in hair regrowth, reduced inflammation, and improved scalp condition, but further studies are needed to confirm long-term efficacy and safety.

This case report highlights a patient who developed cutaneous sarcoidal lesions at the site of platelet-rich plasma injections after COVID-19 infection and vaccination, suggesting possible immune system involvement.

This study found that topical minoxidil 5% foam was effective in promoting hair growth in both the frontal and vertex scalp for men with androgenetic alopecia.

This chapter reviews various dermatological drugs and treatments, highlighting adverse effects, with no new clinical findings reported.

This study found that a hair lotion containing saw palmetto and 10% trichogen veg complex increased total hair count in male patients with androgenetic alopecia over four months, though observer assessments varied.

This review concludes that global literature supports the lipidosterolic extract of Serenoa repens as efficacious and safe for treating lower urinary tract symptoms, with some studies showing equivalence to common pharmacologic agents.

In this study, 68% of patients treated with finasteride showed improved hair growth in male androgenetic alopecia, compared to 38% with Serenoa repens, indicating finasteride's superior efficacy.

This study found that topical cetirizine 1% significantly improved hair density and diameter in patients with androgenetic alopecia, with patients tolerating the treatment well.

This case report describes an 11-year-old girl who experienced hot flashes and menarche after taking a Serenoa repens supplement for telogen effluvium, suggesting a possible but uncertain link between the supplement and hormonal changes.

In this clinical trial, supplementation with Lambdapil® Anti Hair Loss capsules for 6 months significantly improved hair resistance and volume in women and increased the anagen/telogen hair ratio in men, indicating enhanced hair growth compared to the placebo group.

This study found that the dietary supplement RJ-SP4AGA significantly improved hair growth and reduced hair loss in post-menopausal women with androgenetic alopecia over 16 weeks.

This article discusses Serenoa repens (Saw palmetto) for preventing and treating androgenic alopecia, highlighting its phytosterols' role and lack of side effects but reports no new clinical results.

This study found that the extracts of Serenoa repens, when evaluated through chemical, biological, and in silico methods, demonstrated anti-inflammatory, pro-apoptotic, and anti-androgenic activities against prostate cancer cell lines, suggesting potential therapeutic benefits and directing future pharmaceutical development.

This study aimed to evaluate the effectiveness of a hair conditioner containing Serenoa serrulata extract and tocoferol applied 3-4 times per week for 90 days against androgenic alopecia.

Certain skin drugs and topical agents, including some natural extracts and fragrances, can cause allergic reactions. Some hair dyes and extensions, as well as minoxidil, a hair growth treatment, can also cause allergies. Botulinum toxin A can effectively reduce sweat but may have temporary side effects.

This case report describes a 24-year-old woman with androgenetic alopecia who developed sensitivity to topical minoxidil and later to saw palmetto after using a minoxidil and retinoic acid preparation.

This study found that pumpkin seed oil significantly improved hair parameters in females with pattern hair loss, demonstrating potential as a treatment comparable to minoxidil 5% foam.

This study found that topical application of recombinant human MG53 protein mitigated nitrogen mustard-induced skin injuries in mice by preserving epidermal integrity and hair follicle structure.

In 2002, various skin reactions were reported due to different drugs, including allergies, hair loss, skin lesions, and other skin conditions.